Comparing Laser and Ointment Treatments to Traditional Injections for Alopecia Areata A Study on Effectiveness and Safety

Comparative Study of Fractional CO2 Laser with Topical Tacrolimus 0.1 percent and Tofacitinib 2 percent Ointments versus Intralesional Triamcinolone Acetonide in Alopecia Areata a Clinical and Trichoscopic Evaluation - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070279

Enrollment

Registered

2024-07-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L638- Other alopecia areata

Interventions

Intervention1: Fractional Co2 laser: The laser treatment will be administered every 4 weeks for a total of 6 sessions, and topical tacrolimus 0.1% ointment will be applied twice daily for the durati

Eligibility

Inclusion criteria

Inclusion criteria: 1. Alopecia areata denovo cases 2. Treatment free period of at least 4 weeks prior joining to the study.

Exclusion criteria

Exclusion criteria: 1. Patients with alopecia totalis, alopecia universalis, cicatricial alopecia and other causes of alopecia other than AA. 2. Patients with hematological disorders and patients on antiplatelet drugs 3. Pregnant and lactating females 4. Patients with active infections 5. Patients with keloidal tendency.

Design outcomes

Primary

Measure	Time frame
1.Comparison of efficacy in treating alopecia areata between Fractional CO2 laser combined with topical 0.1% ointment, topical tofacitinib 2% ointment, and traditional intralesional triamcinolone acetonide injections.Timepoint: All three treatment modalities will be administered every 4 weeks for a total of 6 sessions, spanning up to 24 weeks. The efficacy comparison will be conducted at the end of 40 weeks.	—

Measure

Time frame

1.Comparison of efficacy in treating alopecia areata between Fractional CO2 laser combined with topical 0.1% ointment, topical tofacitinib 2% ointment, and traditional intralesional triamcinolone acetonide injections.Timepoint: All three treatment modalities will be administered every 4 weeks for a total of 6 sessions, spanning up to 24 weeks. The efficacy comparison will be conducted at the end of 40 weeks.

—

Secondary

Measure	Time frame
1. Trichoscopic evaluation of therapeutic response to the three treatment modalities. 2. Monitoring & evaluation of the safety & tolerability of each treatment approach, including documentation of any adverse effects or complications. Timepoint: Trichoscopic evaluations will be conducted at baseline & then every 8 weeks (i.e., at baseline, week 8, week 16, week 32, & week 40) up to 40 weeks. Safety, tolerability, & side effects will be recorded at each session, accompanied by serial photographs.	—

Measure

Time frame

1. Trichoscopic evaluation of therapeutic response to the three treatment modalities. 2. Monitoring & evaluation of the safety & tolerability of each treatment approach, including documentation of any adverse effects or complications. Timepoint: Trichoscopic evaluations will be conducted at baseline & then every 8 weeks (i.e., at baseline, week 8, week 16, week 32, & week 40) up to 40 weeks. Safety, tolerability, & side effects will be recorded at each session, accompanied by serial photographs.

—

Countries

India

Contacts

Public ContactDr. Eddula Venkata Ravikanth

Apollo Institute of Medical Sciences and Research Chittoor

ravikanthmikado@gmail.com9966789376

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026